T he challenge in hypertension research is the elucidation of the primary genetic causes of elevated blood pressure. It is common knowledge that the basic information on how a cell, an organ, and the whole body function resides within the chromosomes and the individual genes, that is, their nucleotide DNA sequence. The problem with understanding primary (genetic) hypertension in humans is that several genes are involved in the cardiovascular control mechanisms and the genetics are complex. In addition, environmental factors that act over extremely long periods of time (such as diets, physical activity, stress) confound the genotype/phenotype relation individually, within a family, and regionally. So although monogenetic, dominant traits and diseases such as some lipid disorders can be studied with relative ease, polygenetic diseases like human primary hypertension remain puzzles for the future, making well-defined experimental models for research mandatory (for review, see References 1-3). In this review we will focus on three different types of experimental hypertension models, each model representing a specific stage of experimental hypertension research.
Transgenic Rats: New Animal Models in Hypertension Research
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We will discuss the spontaneously hypertensive rat (SHR), first described by Okamoto et al, 4 -5 which was obtained by selective breeding. This rat strain represents, in principle, an experiment of nature. Rats were selected from a normal colony for a specific phenotype, namely, high blood pressure. The hypertension of SHRs clearly is hereditary and genetically determined. These rats, therefore, provide an excellent model for the study of naturally occurring candidate hypertension genes that have accumulated in them. In fact, as will be discussed below, strain-A further refinement in the generation of experimental animal models was the introduction by classic breeding of a mutated vasopressin gene into the genetic background of the SHR. Nature provided us with a mutation of interest for hypertension research: the Brattleboro rats, which exhibit a spontaneous point mutation of the vasopressin gene resulting in a shift of the reading frame and production of a nonfunctional, ineffective protein precursor. These animals produce no vasopressin (AVP) and have a hereditary hypothalamic diabetes insipidus (DI). Introduction of this defective gene into SHRs proved conclusively and definitely that AVP is not necessary for the elevation and maintenance of hypertension. The drawback of this approach is the necessity to wait for spontaneous and natural gene mutations before they can be introduced into new rat strains.
With the availability of molecular biological approaches, it now is possible to design a more rational animal model. Gene technology makes it possible to introduce new, additional genes in normotensive and hypertensive animals. It also is possible, in the mouse, to delete or mutate specific genes, and similar technology is being developed for use in the rat. This marks the important transition from classic breeding, the experiments of nature, to high-tech genetics, which offers previously impossible and unparalleled opportunities. 89 This review of our efforts to develop new animal models of experimental hypertension research is based on previously published reports on the gene analysis in SHRs, 3 -6 the introduction of mutated genes resulting in SHRs with hereditary hypothalamic DI (SHR-DI), 7 and the generation of hypertensive transgenic rats with an additional renin gene TGR(mRen-2 d ) 27 .»-tension occurs frequently (95%). Animal models for primary hypertension therefore are needed, particularly ones with hereditary transmitted hypertension, to study the genetics of this disease. The major difficulty in developing animal models for primary hypertension resides in the disease itself. With respect to pathophysiology, natural history, response to treatment, and complications, the disease is a heterogeneous manifestation, and no uniform abnormality apart from elevated blood pressure yet has been defined. In its early stages, even the classification of "normotensive" and "hypertensive" poses major problems, because blood pressure is a quantitative trait, and the dividing line between normal variations and hypertensive disease is arbitrary.
There is an equally difficult problem with respect to the normotensive control animals. Although normotensive and hypertensive rats usually are derived from one strain, they subsequently are selected for their particular phenotype. In most instances, these substrains are inbred, each developing into a new strain with respect to genotype. It is frequently and erroneously assumed that the genetic differences between these hypertensive and normotensive strains relate solely to the difference in blood pressure. This is only partially true. Many other genes that may be irrelevant to blood pressure control and for which the phenotypes are not monitored may have drifted more or less fortuitously into the two strains. Thus, genotypic differences between strains with or without hypertension may, but also may not, be related to the pathophysiology and phenotypic expression of hypertension.
The critical importance of proper controls recently became evident when the genetic background of different normotensive and hypertensive strains on the one hand and identical strains from different sources on the other hand were studied. 10 Probes to hypervariable minisatellite regions of DNA were used to identify multiple loci scattered over the autosomal chromosomes, producing a complex pattern of fragments ("DNA fingerprint"). When the DNA of SHRs and Wistar-Kyoto (WKY) rats from several sources was compared, it was found that the fingerprints of SHRs were identical but that variability existed in those of WKY rats, indicating genetic heterogeneity between different WKY stocks. These observations confirm the concern that experimental results using control rats from different sources, including commercial ones, may not be directly comparable. This could provide an explanation for some of the conflicting data that exist on the comparative characteristics of SHRs. The various inbred strains of genetically hypertensive rats have trapped (i.e., genetically fixed) different but probably overlapping subsets of specific genetic abnormalities causing high blood pressure. Thus, one expects differences as well as similarities between strains. Each of the rat strains has some unique pathophysiological features linked to the development of hypertension and resembling disorders found in subgroups of hypertensive subjects. Similarly, the individual patient presenting with primary hypertension may have pathophysiological features and single or combined functional defects in, for instance, salt sensitivity, renal electrolyte handling, cellular cation exchange, mineralocorticoid sensitivity, cellular calcium regulation, vascular reactivity, sympathetic tone, or neurogenic factors. Thus, the cause of hypertension in an individual hypertensive patient may closely resemble the disturbances found in one or more of the presently available genetically hypertensive rat strains.
One of the major advantages of the SHR is that it affords opportunities for investigations of basic mechanisms of blood pressure regulation that cannot be done in humans. Most importantly, it is known a priori in an established rat strain whether the individual animal will develop hypertension or not; this will never be the case for human subjects. The foremost advantage of animal studies thus lies in the predictability of genetics and in the prospective comparability and reproducibility of study groups. Invasive procedures that cannot be performed in humans are feasible with animal models. Furthermore, SHRs have proved extremely helpful in studies on the course and the cardiovascular complications of hypertension due to the condensed time window and life span as well as the efficacy of antihypertensive agents.
Without a doubt, rats with genetic, spontaneous hypertension have helped generate a wealth of valuable information to allow precise endocrine and hemodynamic investigation. The limitation of this model, however, resides in the polygenetic nature of the hypertensive disease and the complexity of primary and secondary interactions. One new approach to studying the molecular and genetic basis of primary hypertension is the investigation of gene structure and functions by molecular biological techniques. Analysis of candidate genes for hypertension in SHRs may give insights into the causes of high blood pressure or into the hypertensive process in subsets of humans with primary hypertension.
Candidate Genes for Hypertension in Spontaneously Hypertensive Rats
A relatively small number of major genes, probably four to six, control the manifestation of hypertension 1112 ; 12 additional minor loci also seem to be involved. 13 It thus is possible to study those candidate genes that are thought to be involved in the development and maintenance of primary hypertension, a strategy also termed the "candidate gene" approach. It has to be kept in mind, however, that the existence of a genetic difference between inbred strains selected for the presence or absence of a particular trait may be the result of either genetic selection for this trait or chance fixation by genetic drift, as indicated above. To distinguish between these two possibilities, a number of criteria have to be met, 14 including demonstration of a Mendelian pattern of inheritance of the marker, the presence of a logical relation between the gene or gene product investigated and cardiovascular regulation, and the continued association of genotype and phenotype in a segregating population. Structural differences of candidate genes between hypertensive and normotensive subjects can be determined using various methods, including direct sequencing or analysis of restriction fragment length polymorphisms (RFLPs). RFLP analysis is a powerful tool to screen for alterations in regions of the genome for which hybridization probes are available. 15 - 16 In this review, we will limit our discussion to the renin gene, which was chosen as one likely candidate gene for hypertension. Using RFLP methodology and the criteria outlined above, we have characterized an RFLP affecting the renin gene of normotensive and genetically hypertensive rats and have tested its association with a number of phenotypical parameters important for cardiovascular control.
We have reported that the renin genes of inbred WKY rats and SHRs of the stroke-prone substrain (SHRSP) differ from each other by a 700 bp deletion within the first intron ( Figure 1 ). When compared with the Sprague-Dawley strain, deletional events within intron I are apparent in both the WKY rat and the SHRSP: a minor (approximately 200 bp) deletion is present in the WKY rat, whereas a larger segment (approximately 900 bp) is missing in the SHRSP. In the Sprague-Dawley rat, for which complete sequence information is available, the area affected is characterized by a tandem repeat element consisting of 46 copies of a 37mer characterized by the presence of Nco I and Nla II restriction enzyme cleavage sites. The inherent instability of such regions 1718 makes it very likely that differences in the number of tandem repeats of the repetitive element account for the observed polymorphism between WKY, SHRSP, and Sprague-Dawley rats. The functional significance of structural changes in these variable domains is questionable but not excluded. It also is possible that additional structural differences are present in the renin gene of SHRs. Our data suggest that in the WKY rat, a different segment of the stretch of tandem repeats is affected than in the SHRSP. These findings are in agreement with those recently reported by Samani et al 19 with regard to the SHR and suggest that the renin gene in the SHR and SHRSP may be similar. Rapp et al 20 also have described a polymorphism in the Dahl rat, localized, as in our experiments, to a 2.6 kb Bgl II fragment of the first intron, where a deletion was found in the saltsensitive compared with the salt-resistant strain.
According to these results, the renin gene thus could be considered a genetic marker for hypertension. Crossbreeding of SHRs with WKY rats showed that the two normotensive and hypertensive alleles are propagated in a Mendelian fashion. Evidence for the potential physiological importance of the observed polymorphism (or a closely linked locus), however, relies on experiments testing cosegregation of the hypertensive genotype with the hypertensive phenotype in the F 2 generation, as mentioned above.
In an extensive and detailed study, we have failed to show cosegregation of the renin genotype and arterial blood pressure. Therefore, although the renin gene polymorphism distinguishes between hypertensive and normotensive inbred strains, it does not represent one of the major loci determining blood pressure in the strains we studied, nor is it closely linked to such a locus. 6 This is in agreement with several studies on primary hypertension in humans, which showed no correlation between renin gene RFLPs and blood pressure. 21 " 23 Our results, however, contrast with a similar study performed on the above-mentioned renin gene RFLP in the Dahl strain. 20 There, a significant gene dose effect of the S allele (which characterized the salt-sensitive substrain) on blood pressure was demonstrated in a segregating F 2 colony. This discrepancy may be due to a number of factors, which are discussed elsewhere in detail and which may be related to the methods of studying cardiovascular phenotypes. ' 24 Kurtz et al 25 also have reported cosegregation of blood pressure and a renin RFLP in an F 2 cohort. These experiments were done with male SHRs and female normotensive Lewis rats. Their results are not easily reconciled with the lack of cosegregation of the hypertensive genotype with higher blood pressure in the F 2 cohort in our study. Again, a number of experimental details need to be considered, such as the choice of a genetically distant normotensive strain in the study of Kurtz et al 25 and the exclusive use of male SHRs for mating, which may bias higher blood pressure. 26 -34 Such considerations stress caution as to the possible conclusions to be drawn from these studies involving linkage of genes with a specific phenotype. The lack of correlation of hypertensive genotype and phenotype does not rule out an association of the renin gene RFLP with hypertension in SHRSPs. If the gene dose effect on blood pressure at the specific locus is comparatively minor, cosegregation of the gene and blood pressure will become apparent only if a very large segregating population is studied.
For genomes for which a detailed linkage map has been established, a novel approach to solving the difficult problem of determining the location and number of genes that condition quantitative traits recently has been presented. 35 With the use of sophisticated algorithms, this method allows the highresolution detection and mapping of quantitative trait loci. Provided a linkage map becomes available in the rat, this method ultimately could lead to a much more comprehensive examination of the genome for loci linked to hypertension. In the meantime, other approaches may be helpful. m 46 eoplea of 37mer with Nco I and Nla n clcanf e site 10 pressure, heart rate, and relative changes in arterial blood pressure in response to stress or sodium loading displayed considerable sexual dimorphism. The finding of higher baseline arterial pressures in males compared with females is in agreement with previous studies in humans, 28 mice, 29 and rats 30 and may be related to a conditioning effect of androgens early on during postnatal development. 26 The dissociation between blood pressure and cardiac mass that we found in male F 2 animals and the observation that left ventricular hypertrophy was more severe in the less hypertensive females 6 support the concept that blood pressure is not the sole determinant of cardiac mass in hypertensive cardiac hypertrophy. 31 - 34 There may be direct effects of sex steroids on the cardiovascular phenotypes.
Of particular interest in this respect is the fact that steroids are well known to act directly on gene expression. The quantitatively impressive sexual dimorphism with respect to both blood pressure itself and related parameters indicates that this provides an excellent model for further studies on the cellular and genetic causes. 26 " 27 Interestingly, as will be discussed below, the hypertensive transgenic rat TGR(mi?en-2'')27 exhibits the same sexual dimorphism, male animals having significantly higher blood pressure than females. 8 - 9 Because the only difference of these animals from their normotensive controls is the additional renin gene, this dimorphism may be related to the renin transgene itself but also may indicate a more profound difference in blood pressure regulation between males and females.
We thus can conclude from the experiments in SHRs with naturally occurring hereditary hypertension that a region within the first intron of the renin gene, containing multiple copies of a tandem repeat element, is highly polymorphic among different rat strains. In hypertensive SHRSPs, a particularly large deletion is observed. Studies examining a possible association of this deletion with a number of phenotypical markers important for cardiovascular regulation produced variable results in different laboratories and failed to document clear-cut and unequivocal cosegregation with the renin genotype. These observations correspond to the heterogeneous nature of hereditary hypertension in general. The sexual dimorphism with respect to blood pressure in SHRs, the possible causal link of this phenomenon to the renin gene, and the effects of testosterone on its expression provide future research directions. These studies show the value but also the limitations of the candidate gene approach and represent a step forward toward characterizing differences between various forms of hypertension at the molecular level. Clearly, additional methods are required to understand and define the pathomechanism responsible for primary hypertension.
Introduction of a Mutated Gene: The Spontaneously Hypertensive Rat With Hereditary Hypothalamic Diabetes Insipidus
The insertion of a genetic defect in the synthetic pathway of a blood pressure-regulating factor (hormone or neurotransmitter) offers an elegant way to single out one gene in question without simultaneously interfering with a number of other secondary mechanisms. This approach has been attempted successfully through classic breeding of rats. 36 Rats with hereditary hypothaJamic DI, which have a genetic defect in AVP synthesis 37 -39 ( Figure 2 ), and rats with genetically determined hypertension, SHRSPs, 5 were available. The SHRSPs had decreased levels of AVP in the brain and blood. 36 - 40 The hypothesis therefore was formulated that AVP may not be essential for the development of hypertension in SHRSPs. A new strain of hypertensive rats with hypothalamic DI (SHRSP-DI) was obtained by crossbreeding SHRSPs with DI rats. 7 For this, SHRSPs, WKY rats, Brattleboro rats homozygous for DI, and Long-Evans (LE) control rats were used. The DI rats were identified by urine volume and a drinking test. The genetic strategy was to try to accumulate SHR genes as well as DI alleles in a subline of the F, generation. This was achieved by inbreeding of DI/+ animals and then backcrossing with the SHRSP stock colony. This procedure led to a stepwise accumulation of SHR genes and a reappearance of DI animals from the DI/+XDI/-intercrosses. 7 Results with these SHRSP-DI animals showed that blood pressure developed essentially the same way as in SHRSPs with respect to absolute levels and time course (Figure 3 ). The mortality of the resulting SHRSP-DI offspring was high. This may in part have been caused by dehydration. In animals successfully raised to adulthood, a complete analysis of the hormonal, electrolyte, volume, and hemodynamic status was performed. AVP was not measurable in the plasma of SHRSP-DI and DI rats, nor could it be found in the hypothalamus or pituitary. The AVP content in the hypothalamus was reduced in SHRSP compared with age-matched WKY rats, but similar amounts were found in the pituitary of SHRSP, WKY, and LE rats (Figure 4) .
The oxytocin content in the pituitary was markedly reduced in SHRSP-DI and DI rats as compared with SHRSP, WKY, and LE rats. During water deprivation, SHRSP-DI and DI rats were unable to concentrate their urine adequately but could do so threefold to fourfold after subcutaneous administration of AVP, indicating that their kidneys functioned well and that the water loss was due to the lack of hypothalamic AVP.
In all animals, a positive immunocytochemical reaction was observed in the hypothalamus for oxytocin. Results of AVP immunocytochemistry were negative in DI and SHRSP-DI rats. As for the Brattleboro rat, mRNA for AVP could be demonstrated in the hypothalamus by specific hybridization methods. 41 This stresses how important it is to investigate gene activity both at the transcriptional (mRNA) and at the translational (protein, peptide) levels to assess the activity of the system and the cellular level at which gene mutations become effective. CY3  PKE CLT  PRO  SER  ILE  CTS  CYS ALA   LCD  CLT  CYS  PKE  LEU  CLY THR  ALA GLU  ALA LEU ASP  GLU  LEU GLY  CTS  PHE  LEU  CLY THR  ALA GLU ALA  LEU  ARC CYS  CLM CLU GLU ASH TT*   LEU  PRO  SES  PRO  CYS  GUI  SER  GLY GUI  LTS  PRO  CYS  CLY  SER  CLY CLT  ASG CYS 
CTS CYS ALA C C C C C A A A C C C C C C T C C T T C C C C C C C A C C A T C T C C T C C C C C C C T C C T T C C C C C C C A C C A T C T C C T C C C C C
ARC CYS CLM CLO CLU ASM TV* C G C T C C T T C C T G C G C A C C G C C G A C C C C C T C C G C T C C C A G G A C C A G A A C I A C G C C C A C C C C C T C C C C T C C C A C C A C C A C A A C T A C ASP CLU C A C C A C C T C C A C C A C C T C C G C T C C T T C C T C C C C A C C
ALA ALA C T C C C C T C G C C C T C C C A G T C T C C C C A C A A C C C T T C C C C A A G C C C A G G C C C C T C C C C T G C C C T C C C C T C C C C C T G C C A G T C T G G C C A G A A G C C T T G C G C A A C C G A C G C C C C T C C C C T C C C
I C C C C G C A T C T C C T G C A G C G A T C C C G G C C A T C T G C T G C A C C G A T G
0 UC 1U ID MA AU UA XT
Gene
• umtoa 7
G T G C C C A C A A A G C C A C C C G G G C T G A G C A T G C C C k A T C G T C C C C A C A A A C C C A C G C G C C C T G A G C A T C G C C A A T G
Dtebatn bnlpidu* rat 
FIGURE 2. Top panel: Nucleotide sequence of exon B of the vasopressin gene. Note the point mutation (arrow) with a deleted G nucleotide and the shift of the reading frame leading to a nonsense precursor protein and inactive translation product (see References 37, 38, and 39). Normal nucleotide sequence on top (N), with that for diabetes msipidus (D.I.) below. Respective derived amino acid sequences also are indicated. Bottom panel: Schematic outline of the normal vasopressin gene (left) and the mutated gene of diabetes insipidus rats (right). The localization of the point mutation (top) is indicated by the black bar The transcription product (mRNA) and the translation product (neurophysm) (NP) of the mutated diabetes insipidus gene lead to a nonsense protein that then blocks the endoplasmic reticulum of the vasopressin (AVP)-producing cells in the hypothalamus, and thus no active peptide is transported into the posterior pituitary (modified from References 38 and 39). SP, signal peptide; GP, gfycoprotein.
In conclusion, the insertion of the mutated DI gene into SHRs clearly demonstrated that AVP is not essential for the development and maintenance of high blood pressure in SHRSPs. This first model of hypertensive rats with a known single genetic defect for hormone synthesis offered a new approach to the study of gene involvement in blood pressure regulation and the pathophysiology of hypertension. 742 However, the necessity with this approach to wait for the rare and serendipitous event of a naturally occurring spontaneous gene mutation and the ensuing classic breeding approach to introduce the defect into a hypertensive genetic background make this procedure unsystematic and cumbersome in practice. The availability of transgenic techniques enables the extension of these procedures to add or modify the activity of genes on a rational basis and in a systematic way in any natural or manipulated normotensive or hypertensive animal.
Testing Genes In Vivo: Transgenic Techniques The generation of animals with defined genetic alterations has become feasible through the transfer of genetic material (DNA) into the germline ( Figure  5 ), which results in transgenic animals (see References 43-49). In principle, genes can be added and also deleted, leading to the systematic testing of gene function and its relation to a specific phenotype, for example, blood pressure, in vivo The most common technique to produce transgenic animals consists of injecting the desired transgene DNA into the pronucleus of a one-cell embryo 43 -49 that then is implanted into a foster mother ( Figure  5A ). In a well established system, approximately 25% of all injected embryos that have been brought to term will result in transgenic animals. The transgene then will be passed on from parent to progeny in a Mendelian manner, allowing propagation of a new strain of animals. The nature of the gene construct but also in part its integration site into the genome determines its tissue-and time-specific handling in the new transgenic animals 43 -49 ( Figure 5B ).
FIGURE 3. Water intake, mean arterial blood pressure, and heart rate in spontaneously hypertensive rats with hereditary hypothalanuc diabetes insipidus (SHRDI) compared with Wistar-Kyoto (WKY) rats, spontaneously hypertensive rats of the stroke-prone strain (SHRSP), diabetes insipidus (DI) rats, and Long-Evans (LE) rats. Note the greater water intake in
Higher levels of refinement, specificity, and resolution in the development of transgenic animal models are possible by another, more recent strategy, that is, gene targeting by homologous recombination. 49 ' 68 This involves the isolation of inner mass cells from blastocysts and their maintenance in culture as pluripotent embryonic stem (ES) cells. The transgene DNA construct targeting an endogenous gene locus then is introduced into these ES cells. Cells with the desired alteration of the endogenous gene then can be selected and identified by specific methods. 68 Successfully transfected cells are placed into recipient blastocysts, which eventually will result in chimeric animals that contain the altered genetic information in their germline. Transgenic animals then can be established by the conventional breeding of these germline chimeras. The potential of homologous gene targeting for the creation of new animal models for genetic disorders, including hypertension, cannot be overestimated. 49 ' 68 Although the insertion of the transgene into the recipient chromosomes is random if the microinjection technique is used, homologous recombination in ES cells permits targeted incorporation of the transgene into the desired locus, and this can be carried out before the production of transgenic animals. This potentially avoids the disruption or modulation of unknown genes and insertional artifacts that have to be considered when the microinjection technique is applied.
The ES cell methodology has been used for targeted deletions of endogenous genes, permitting the study of the phenotype without a functional gene. Attenuation of gene function also can be achieved by microinjection of specific DNA constructs that have a reverse Figure 5C ). In this procedure, the gene to be neutralized, the endogenous form of which is transcribed in the 5'-3' orientation ("sense"), is injected into the fertilized oocytes in a construct designed to transcribe its reverse 3'-5' orientation ("antisense"). This transgene construct produces a complementary RNA that hybridizes with the endogenous mRNA and inhibits effective translation of the gene. Both methods, homologous recombination or antisense neutralization, thus will delete or inhibit a gene. Both approaches have been applied successfully in transgenic mice. 69 In the future, such manipulation will be a feasible alternative to the classic breeding of SHR-DI to delete gene function. These and other "loss of function" techniques eventually will enable systematic and specific testing gene by gene in vivo and make the assessment of the importance of candidate genes for hypertension a reality.
Testing of a candidate gene in transgenic animals will provide information on the involvement of that gene in a given phenotype. Most transgenic experiments so far have been done in mice or farm animals. To date, the mouse genome is much better characterized than that of any other higher species, and in particular, mouse genetics has been more intensively studied than that of the rat. For our experiments investigating cardiovascular phenotypes, we have, however, tried to generate for the first time transgenic rats. The following considerations supported transgenic rats as an experimental animal model in hypertension research. The rat, more often than any other species, has been used in basic pathophysiological and therapeutic hypertension research. We therefore have at our disposal a wealth of physiological data about hypertensive rat models. Mice are poorly suited for this type of experimentation, aad bigger animals would be impractical. In contrast to mice, the molecular biological and genetic studies in rats can easily be complemented by extensive pathophysiological, hemodynamic, electrophysiological, endocrinological, and pharmacological investigations using well established, reliable methods.
Addition of a Ren in Gene: The Hypertensive
Transgenic Rat TGR(mRen-2 4 )27
In our studies investigating the functional cardiovascular consequences of adding a candidate gene in a transgenic rat, the mouse DBA/Ren-2 d gene was chosen for reasons discussed elsewhere in detail.
-
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-5170 This gene previously had been characterized in transgenic mice and therefore could be expected to be highly expressed in certain tissues; it also yields a nonglycosylated translation product that can be anticipated to result in a protein with altered secretion. This was of particular interest for studies on tissue renin. hypertension. Two independent hypertensive lines now have been established. The consistent segregation of hypertension with the transgene in these animals and the fact that the hypertensive phenotype was observed in all the other positive founder animals are strong arguments in favor of the transgene being causally related to high blood pressure. This was an important finding because, as mentioned above, with the use of microinjection the transgene can be inserted into any locus of the chromosome and thereby also can produce transgene-unrelated phenotypes due to fortuitous mutations associated with the transgene integration at a given insertion site.
For the establishment of a new transgenic strain, the offspring of the transgenic founder animals must be bred to homozygosity to permit extensive reproducible experimentation. The breeding schedule of founder animal number 27 is indicated in Figure 6 . The homozygous transgene-positive animals were even more hypertensive than the heterozygous animals, with blood pressures reaching 300 mm Hg.
Breeding of these animals therefore had to be done under antihypertensive therapy, which was accomplished with low-dose converting enzyme inhibitor treatment (captopril, 10 mg/kg). To date, the homozygous animals have been used to establish the breeding colony, and no major pathophysiological experiments have been performed. Crossbreeding of homozygous animals (e.g., male 504) with SpragueDawley outbred female animals resulted in heterozygous animals (e.g., animals 720-729) ( Figure 6 ). These animals remained untreated and are being used for further experimentation.
Hypertension develops very rapidly in homozygous and heterozygous animals, which reach blood pressures of 200 mm Hg and higher at 8 weeks of age. Interestingly, blood pressure in males is much higher than in females, with a difference of more than 60 mm Hg (see above). Analysis of the renin-angiotensin system in the plasma revealed that all components, that is, angiotensin I, angiotensin II, and plasma renin, were suppressed in both male and female transgenic animals as compared with their negative controls. Kidney renin activity was equally suppressed. Preliminary experiments with an isolated kidney preparation showed that virtually no renin was secreted from the transgenic kidneys (K. Munter et al, unpublished data). The suppression of kidney renin also was confirmed by immunocytochemistry. Specific RNase protection analysis of the Ren-2 1 transgene and the endogenous rat renin gene showed that both the endogenous gene and the transgene are being expressed in the kidney. The reasons for this are not known at the present time, but one probable explanation would be that the extremely high blood pressure may feed back on the kidney via baroreceptors and suppress kidney and plasma renin (Figure 7) . Interestingly, the plasma prorenin level is about 20-fold higher in transgenic animals as compared with their negative controls. Because the kidney is excluded as a source of prorenin, extrarenal sources must be assumed. Indeed, several tissues express the transgene at very high levels, including the adrenal gland, which expresses mouse Ren-2 mRNA 1,000-fold higher than endogenous rat renin mRNA levels and has about four times higher renin enzyme activities than controls. In addition, Ren-2 d transcripts were detectable in the testis, coagulation gland, thymus, several parts of the brain, arterial tissue, aorta, and small intestine. Interestingly, renin mRNA was not observed in the submaxillary gland of transgenic rats. This is of special interest because in the mouse the Ren-2 1 gene is highly expressed in this organ. In principle, plasma prorenin could originate from all these extrarenal sources. One of the most likely organs contributing to plasma prorenin is the adrenal gland. In fact, primary cell cultures of adrenal glands from transgenic animals secreted large amounts of prorenin (M. Bader et al, unpublished data). Adrenalectomy led to a significant, though transient, reduction of plasma prorenin and blood pressure.
It thus appears that the TGR(mRen-2 d )27 animals represent a low renin hypertensive animal model. Whether they correspond to low renin primary hypertension in humans remains to be investigated. In preliminary experiments, we found slightly elevated aldosterone levels in the transgenic animals. These would not be sufficient, however, to explain the extremely high blood pressure (Figure 8) . Further experiments are needed in this respect. Blood pressure can be reduced effectively in these animals by treatment with converting enzyme inhibitors at a low dose of 10 mg/kg daily as compared with the 50 mg usually required in SHRs for antihypertensive treatment. This would indicate that the blood pressure may be dependent on the conversion of angiotensin I to angiotensin II, but other mechanisms, including kinins and prostaglandins, still need to be examined. Before the contribution of angiotensin II can be confirmed or rejected, studies with angiotensin receptor antagonists or angiotensin antibodies must be performed systematically. Interesting hypotheses have been formulated concerning possible unconventional actions of prorenin with respect to kidney function or local angiotensin generation. 7980 These transgenic animals with high plasma prorenin and low angiotensin II levels could represent a suitable model to investigate such postulated mechanisms further. The possibility that kidney renin is pressure regulated and suppressed whereas tissue renin and prorenin, especially in the adrenal gland, apparently are not raises another interesting aspect in these animals.
The pathophysiological basis for the elevated blood pressure in the TGR(mRen-2 d )27 animals still is unclear. The data available to date make these transgenic hypertensive animals an interesting model for cardiovascular research. They unequivocally show that renin can elevate blood pressure without activation of the classic kidney/plasma hormonal reninangiotensin system. The data from these animals certainly support the possibility of extrarenal renin being involved in the development and maintenance of hypertension as well as end-organ damage. 71 " 79 More detailed investigations of the ontogenic development of plasma tissue renin and its relation to blood pressure as well as pharmacological studies should lead to more definite answers to the above questions.
Conclusions
There is no doubt that transgenic methodology, especially transgenic rats, has opened a new era in hypertension research. Each of the animal models described above -SHRSP-DI rats with a naturally occurring gene defect and the transgenic animalshas advantages and disadvantages. With the possibility of a more rational approach and molecular design of new animal models, we will be able to answer much more specific questions than was previously possible, including the use of tissue-specific and cell type-specific promoters to study the effects of gene expression in particular areas of the cardiovascular system. Antisense inhibition as well as homologous recombination will enable us to explore the loss of gene function. The introduction of human genes into lower vertebrates could change the path of clinical pharmacology by permitting the study of humanspecific mechanisms and substances in rats and tissue cultures derived from transgenic animals.
The new transgenic animal models will be specifically designed on a rational basis and will allow us to answer precise questions as to the mechanisms involved in the hypertensive process as well as make more specific approaches to therapy available. Many transgenic mice and rats will be available soon, but the results and answers will not be fast and easy; collaborative and responsible efforts are warranted also in view of the ethical dimensions involved in this research.
